key: cord-0687920-mibvdm1r authors: Baccellieri, Domenico; Bilman, Victor; Apruzzi, Luca; Monaco, Fabrizio; D’Angelo, Armando; Loschi, Diletta; Melissano, Germano; Chiesa, Roberto title: A case of Covid-19 patient with acute limb ischemia and heparin resistance date: 2020-06-24 journal: Ann Vasc Surg DOI: 10.1016/j.avsg.2020.06.046 sha: 53360a90466cdbcf3304ed2ff85630c830ea17d6 doc_id: 687920 cord_uid: mibvdm1r Heparin resistance is an uncommon phenomenon defined as the need for high dose unfractionated heparin (UFH) of more than 35,000 IU/day to achieve the target activated partial thromboplastin time ratio or the failure to achieve the desired activated clotting time after a full UFH dose. This rare phenomenon is being more commonly observed in Covid-19 patients in a hypercoagulable state. We describe a Covid-19 patient confirmed by reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay, with acute limb ischemia, who developed heparin resistance. The patient was managed by the departments of Vascular Surgery, Anesthesia and Intensive Care, and the Coagulation Service and Thrombosis Research from San Raffaele Scientific Institute, Milan, Italy. Covid-19 patients and an inflammatory pathway involving endothelium activation has 72 been suggested to justify clots formation. [2, 3, 5-8] 73 The treatment of thrombosis in the setting of a deep hypercoagulable state, such 74 in Covid-19 patients, may be hampered by the inability to achieve the target aPTT when 75 treating with unfractionated heparin (UHF). [9] This rare phenomenon is called heparin 76 resistance (HR), which can be defined by the use of high doses of UFH to raise the aPTT 77 and activated clotting time (ACT) to within therapeutically desired ranges. [10] 78 Herein is described a case of a Covid-19 patient who developed heparin 79 resistance in the setting of acute limb ischemia associated with acro-ischemia. The The patient was admitted to Covid-19 ward and treated with non-invasive 100 ventilation, ceftriaxone, and enoxaparin 6,000 anti-Xa IU once a day as antithrombotic 101 prophylaxis. During the first 48 hours, the patient did not show any further clinical 102 deterioration. However, from the third day after the admission, there was a progressive 103 increase of the platelet count (443 x10 9 /L), D-dimer (3.73 µg/mL), C-reactive protein 104 (229 mg/L) and worsening of the gas exchange. Consequently the patient was intubated 105 and moved to Covid-19 Intensive Care Unit (ICU). 106 On day 5, the patient suffered pain, numbness, and coldness of the right lower 107 limb along with a massive augmentation of the D-dimer (> 20µg/ml). A Duplex 108 ultrasound scan (DUS) showed complete occlusion of the right iliac and femoro-109 popliteal arteries, for which it was performed an emergent revascularization of the lower 110 limb under general anesthesia. A 20G catheter was inserted in the right radial artery to 111 monitor the invasive blood pressure. To achieve an ACT above 250 seconds, three 112 boluses of 1000 UI each of intravenous UFH were required after the administration of a 113 loading dose of 5000 UI. To maintain the ACT target, further 6,000 IU of UFH were 114 added. A right lower limb conventional thrombectomy was successfully performed with 115 a Fogarty catheter using multiple accesses (femoral and below-the-knee popliteal). An 116 intra-operative DUS control showed a biphasic flow pattern on the treated arteries. 117 During the surgery, the sudden flattening of the arterial wave, the coldness and pallor of 118 the right upper limb were highly suggestive of limb ischemia. The clinical suspicion was 119 confirmed by the intra-operative DUS, which detected the thrombosis of the right 120 brachial artery. Then, a right upper limb thrombectomy was successfully performed with 121 restoring of radial artery patency. The patient was discharged from the operating theatre 122 with a continuous infusion of 1,000 IU/h of UFH. Notably, an aPTT ratio of 1.92 was 123 obtained only after the increase of the UHF infusion rate to 2,000 IU/h (more than 6 35,000 IU/day). Nevertheless, the aPTT ratio dropped to 0.86 during the first post-125 operative day leading to in further increase of the amount of UHF administered. The 126 day after, the occurrence of a reactive thrombocytosis accounted for a reduction of the 127 aPTT ratio from 2.54 to sub-optimal values. Since the anti-factor Xa assay was below 128 the therapeutic range (0.34 IU/mL), the UFH was shifted to 8,000 of enoxaparin twice a 129 day. Over the two following days, D-dimer decrease to 0.72 µg/mL and the anti-Xa 130 activity ranged between 0.60 to 0.77 IU/mL. During this period, a high dosage (0.25 131 µg/kg/min) of norepinephrine was needed to treat hypotension. 132 On the 6 th post-op day, the patient presented a bilateral persistent acro-ischemia 133 of the lower extremities, including finger/toe cyanosis, skin bulla, and dry gangrene 134 ( Figure 1A ) with patency of lower limb arteries at the DUS. Therefore, prostaglandin E-135 1 infusion at the dosage of 60mcg twice a day was administered. Five days later the 136 patient was discharged from the ICU to the medical Covid-19 ward and twenty days 137 later from the hospital with oral anticoagulation. 138 At 2 months follow-up no further thromboembolic events occurred. A slow 139 reduction of D-dimer levels from 3.3 µg/mL to 1.6 µg/mL was observed. Detailed 140 laboratory findings at the last follow-up are summarized in Table 1 . The evolution of the 141 acro-ischemic lesions, characterized by gradual improvement without the need of major 142 amputation, is shown in figure 1 Heparin resistance is often observed during cardiovascular operations, mainly in 157 procedures that require cardiopulmonary bypass. [12] HR is defined as the need for a 158 high dose of UFH of more than 35,000 IU/day to achieve the target aPTT ratio or the 159 failure to achieve the desired ACT after a full UFH dose. Predictors of HR are age (> 65 160 years), ATIII activity less than or equal to 60%, platelets greater than 300 x 10 9 /L, and 161 increased factor VIII and fibrinogen levels. Platelet count (x10 9 /L) 405 Leucocytes (10 9 /L) 11.6 Lymphocytes (10 9 /L) 0.6 Hemoglobin (g/L) 15.7 Protrombine time ratio 1.06 aPTT ratio 0.84 D-dimer (µg/mL) > 20 Fibrinogen (mg/dL) 740 Platelet count (x10 9 /L) 285,000 Leucocytes (10 9 /L) 8.4 Lymphocytes (10 9 /L) 1.7 Hemoglobin (g/L) 13.3 Protrombine time ratio Angelo: contributed to the concept, analysis/interpretation of data, critical 200 writing and revising intellectual content Diletta Loschi: contributed to the concept, analysis/interpretation of data, critical writing 202 and revising intellectual content contributed to the concept, critical writing and revising intellectual Roberto Chiesa: contributed to the concept, critical writing and revising intellectual Clinical course and risk factors for mortality of adult 211 inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Microvascular COVID-19 lung 214 vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical 215 acute respiratory distress syndrome working hypothesis Endothelial cell infection and endotheliitis 218 in COVID-19 Clinical features of patients infected with 2019 220 novel coronavirus in Wuhan, China. Lancet. Epub ahead of print 2020 Venous and arterial thromboembolic 223 complications in COVID-19 patients admitted to an academic hospital in Milan Epub ahead of print 2020 High incidence of venous thromboembolic 227 events in anticoagulated severe COVID-19 patients The "venous perspective" in Lombardia 230 (Italy) during the first weeks of the COVID-19 epidemic during the first month of the COVID-19 outbreak Epub ahead of print Thromboembolic events and apparent 237 heparin resistance in patients infected with SARS-CoV-2 To be or not to be a case of heparin resistance ISTH interim guidance on recognition 242 and management of coagulopathy in COVID-19: A Comment Predictors of Heparin Resistance 245 Before Cardiovascular Operations in Adults Abnormal coagulation parameters are associated 248 with poor prognosis in patients with novel coronavirus pneumonia